Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

Braveheart Bio (BRVE) will present two abstracts at the American Heart Association Scientific Sessions on November 6, 2026, in Chicago.

Rhea-AI Summary

Braveheart Bio (BRVE) will present two abstracts at the American Heart Association Scientific Sessions on November 6, 2026, in Chicago. A late-breaking presentation will cover 52-week extension data for BHB-1893 in obstructive hypertrophic cardiomyopathy. The other will address diastolic function in non-obstructive hypertrophic cardiomyopathy, drawing on laboratory studies and patients.

Key Figures

Extension period: 52 weeks

Extension period

52 weeks

BHB-1893 presentation in obstructive HCM; results are upcoming

Key Terms

diastolic function, cardiac myosin inhibitor

2 terms

diastolic function medical

"Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy"

Diastolic function is the heart’s ability to relax and fill with blood between beats, like a balloon that must loosen to take in air before the next squeeze. It matters to investors because impaired filling can drive demand for drugs, devices, hospital care and long‑term treatment costs, influence regulatory reviews and trial outcomes, and affect productivity and insurance risk — all of which can change a company’s revenues and valuations.

cardiac myosin inhibitor medical

"a Next-Generation Cardiac Myosin Inhibitor"

A cardiac myosin inhibitor is a type of drug that directly reduces the force of heart muscle contractions by blocking the motor protein (myosin) that drives each heartbeat; think of it as slightly easing the pressure on an overworking engine so it doesn’t overexert itself. It matters to investors because these medicines can change treatment options, regulatory pathways, and revenue prospects for companies developing therapies for conditions where the heart is too strong or stressed, while carrying clinical and safety risks that affect valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced two upcoming presentations, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM, at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, IL. Following the presentations, copies of the presentation materials will be available in the Investors section of the Braveheart Bio website.

Oral Abstract Presentation

Title: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients
Presenter: Carlos del Rio, Ph.D., Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Abstract Oral Presentations
Session Time: 9:45 AM – 10:45 AM CT
Presentation Time: 10:15 AM – 10:25 AM CT
Location: Room S406A, McCormick Place

Late-Breaking Oral Abstract Presentation

Title: Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period
Presenter: Xueyi Wu, M.D., Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China​
Date: Friday, November 6, 2026
Session Title: Hypertrophic Cardiomyopathy Medical Society Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:15 PM – 2:25 PM CT
Location: Room S406A, McCormick Place

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com